MedTrace Logo

Effects of Caffeine on Elite Weightlifting Performance

NCT07520864 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-04-09

No results posted yet for this study

Summary

Weightlifting is a high-intensity strength-power sport where performance depends on maximal force, power output, and technical execution in the snatch and clean and jerk. Due to the sport's short-duration efforts, the ATP-PCr system predominates, with glycolysis supporting recovery between attempts. Given these demands, ergogenic aids are commonly used. While some supplements show limited or inconsistent evidence, caffeine stands out as one of the most well-supported for enhancing strength and power, mainly through central nervous system stimulation. Although its benefits are well documented in other strength sports, research specifically in Olympic weightlifting is scarce. Therefore, this study aimed to examine the effects of caffeine on neuromuscular and competition performance in elite weightlifters, hypothesizing a positive effect.

Conditions

  • Athletes

Interventions

DIETARY_SUPPLEMENT

Placebo

Participants ingested an identical opaque capsule containing an inert substance (cellulose; Guinama, Valencia, Spain). The capsule was also consumed with 200 mL of water under researcher supervision. This condition served as a control to compare against the caffeine condition while maintaining blinding.

DIETARY_SUPPLEMENT

Caffeine

Participants ingested an opaque capsule containing 3 mg·kg-¹ of anhydrous caffeine (HSN, Granada, Spain). The capsule was consumed with 200 mL of water under researcher supervision to ensure compliance. This condition was designed to evaluate the ergogenic effects of caffeine on neuromuscular and weightlifting performance.

Sponsors & Collaborators

  • Universidad Francisco de Vitoria

    collaborator OTHER

  • Universidad Rey Juan Carlos

    collaborator OTHER

  • Universidad Pontificia Comillas

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
16 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2026-03-15
Completion
2026-03-25

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07520864 on ClinicalTrials.gov